Literature DB >> 22509505

Drugs: An injection of hope.

Duncan Graham-Rowe.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22509505     DOI： 10.1038/nature11109

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.

Authors:  Janice Wong; Tara Gomes; Muhammad Mamdani; Michael Manno; Paul W O'Connor
Journal:  Can J Neurol Sci       Date:  2011-05       Impact factor: 2.104

2.  Oral fingolimod (FTY720) for relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Jack Antel; Giancarlo Comi; Xavier Montalban; Paul O'Connor; Chris H Polman; Tomas Haas; Alexander A Korn; Goeril Karlsson; Ernst W Radue
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.

Authors:  Sha Mi; Xinhua Lee; Yinghui Hu; Benxiu Ji; Zhaohui Shao; Weixing Yang; Guanrong Huang; Lee Walus; Kenneth Rhodes; Bang Jian Gong; Robert H Miller; R Blake Pepinsky
Journal:  Nat Med       Date:  2011-07-03       Impact factor: 53.440

4.  LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury.

Authors:  Benxiu Ji; Mingwei Li; Wu-Tian Wu; Leung-Wah Yick; Xinhua Lee; Zhaohui Shao; Joy Wang; Kwok-Fai So; John M McCoy; R Blake Pepinsky; Sha Mi; Jane K Relton
Journal:  Mol Cell Neurosci       Date:  2006-09-29       Impact factor: 4.314

5.  Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Authors:  Joanne L Jones; Jane M Anderson; Chia-Ling Phuah; Edward J Fox; Krzysztof Selmaj; David Margolin; Stephen L Lake; Jeffrey Palmer; Sara J Thompson; Alastair Wilkins; Daniel J Webber; D Alastair Compston; Alasdair J Coles
Journal:  Brain       Date:  2010-07-21       Impact factor: 13.501

6.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Authors:  Gavin Giovannoni; Giancarlo Comi; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Peter Chang; Anthony Hamlett; Bruno Musch; Steven J Greenberg
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

7.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

Review 8.  LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.

Authors:  Richard A Rudick; Sha Mi; Alfred W Sandrock
Journal:  Expert Opin Biol Ther       Date:  2008-10       Impact factor: 4.388

9.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Authors:  Joanne L Jones; Chia-Ling Phuah; Amanda L Cox; Sara A Thompson; Maria Ban; Jacqueline Shawcross; Amie Walton; Stephen J Sawcer; Alastair Compston; Alasdair J Coles
Journal:  J Clin Invest       Date:  2009-06-22       Impact factor: 14.808

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245
  10 in total
  1 in total

1.  Synthesis and characterization of a novel gadolinium-based contrast agent for magnetic resonance imaging of myelination.

Authors:  Luca Frullano; Junqing Zhu; Robert H Miller; Yanming Wang
Journal:  J Med Chem       Date:  2013-02-18       Impact factor: 7.446
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.